F
Frederick R. Appelbaum
Researcher at Fred Hutchinson Cancer Research Center
Publications - 696
Citations - 73648
Frederick R. Appelbaum is an academic researcher from Fred Hutchinson Cancer Research Center. The author has contributed to research in topics: Transplantation & Myeloid leukemia. The author has an hindex of 127, co-authored 677 publications receiving 66632 citations. Previous affiliations of Frederick R. Appelbaum include City of Hope National Medical Center & University of New Mexico.
Papers
More filters
Journal ArticleDOI
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Döhner,Elihu H. Estey,David Grimwade,Sergio Amadori,Frederick R. Appelbaum,Thomas Büchner,Hervé Dombret,Benjamin L. Ebert,Pierre Fenaux,Richard A. Larson,Ross L. Levine,Francesco Lo-Coco,Tomoki Naoe,Dietger Niederwieser,Gert J. Ossenkoppele,Miguel A. Sanz,Jorge Sierra,Martin S. Tallman,Hwei-Fang Tien,Andrew H. Wei,Andrew H. Wei,Bob Löwenberg,Clara D. Bloomfield +22 more
TL;DR: An international panel to provide updated evidence- and expert opinion-based recommendations for diagnosis and management of acute myeloid leukemia in adults includes a revised version of the ELN genetic categories, a proposal for a response category based on MRD status, and criteria for progressive disease.
Journal ArticleDOI
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.
Hartmut Döhner,Elihu H. Estey,Sergio Amadori,Frederick R. Appelbaum,Thomas Büchner,Alan Kenneth Burnett,Hervé Dombret,Pierre Fenaux,David Grimwade,Richard A. Larson,Francesco Lo-Coco,Tomoki Naoe,Dietger Niederwieser,Gert J. Ossenkoppele,Miguel A. Sanz,Jorge Sierra,Martin S. Tallman,Bob Löwenberg,Clara D. Bloomfield +18 more
TL;DR: An international expert panel is provided to provide updated evidence- and expert opinion-based recommendations for the diagnosis and management of AML, that contain both minimal requirements for general practice as well as standards for clinical trials.
Journal ArticleDOI
Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study
Marilyn L. Slovak,Kenneth J. Kopecky,Peter A. Cassileth,David H. Harrington,Karl S. Theil,Anwar Mohamed,Elizabeth Paietta,Cheryl L. Willman,David R. Head,Jacob M. Rowe,Stephen J. Forman,Frederick R. Appelbaum +11 more
TL;DR: Cytogenetic risk status is a significant factor in predicting response of AML patients to therapy; however, to tighten treatment correlates within genetically defined AML subsets, a significantly larger leukemia cytogenetic database is warranted.
Journal ArticleDOI
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
Richard Stone,Sumithra J. Mandrekar,Ben L. Sanford,Kristina Laumann,Susan Geyer,Clara D. Bloomfield,Christian Thiede,Thomas W. Prior,Konstanze Döhner,Guido Marcucci,Francesco Lo-Coco,Rebecca B. Klisovic,Andrew H. Wei,Jorge Sierra,Miguel A. Sanz,Joseph Brandwein,Theo de Witte,Dietger Niederwieser,Frederick R. Appelbaum,Bruno C. Medeiros,Martin S. Tallman,Jürgen Krauter,Richard F. Schlenk,Arnold Ganser,Hubert Serve,Gerhard Ehninger,Sergio Amadori,Richard A. Larson,Hartmut Döhner +28 more
TL;DR: The addition of the multitargeted kinase inhibitor midostaurin to standard chemotherapy significantly prolonged overall and event‐free survival among patients with AML and a FLT3 mutation.
Journal ArticleDOI
Methotrexate and Cyclosporine Compared with Cyclosporine Alone for Prophylaxis of Acute Graft versus Host Disease after Marrow Transplantation for Leukemia
Rainer Storb,H. Joachim Deeg,John Whitehead,Frederick R. Appelbaum,Patrick G. Beatty,William I. Bensinger,C. Dean Buckner,Reginald A. Clift,Kristine Doney,Vernon T. Farewell,J. D. Hansen,Roger Hill,Lawrence G. Lum,Paul J. Martin,Robert W. McGuffin,Jean E. Sanders,Patricia S. Stewart,Keith M. Sullivan,Robert P. Witherspoon,Gary Yee,E. Donnall Thomas +20 more
TL;DR: It is concluded that the combination of methotrexate and cyclosporine is superior to cyclOSporine alone in the prevention of acute graft versus host disease after marrow transplantation for leukemia, and that this therapy may have a beneficial effect on long-term survival.